About

Somatolink Foundation, Inc., a Delaware Public Benefit Corporation, is a research-based oncogenomics services organization, with a public benefit and goal to provide both affordable, equitable, and sustainable oncogenomic services, biomarker development and therapeutic discovery by leveraging an Expert-for-Patient Research Network (the ISOPROG-Somatolink EPFP Research Network).  This public benefit is realized by a unique operational model of personalized medicine, which returns the patient’s  bioassets at the center and ownership of their own healthcare.  Together with a portfolio of unique biotargets in solid cancer and psoriasis, Somatolink, in conjunction with ISOPROG is building out an organizational and computational framework to manage and perform research on a patient’s bioassets from biobanking through personalized clinical decision and drug discovery.

The ISOPROG-Somatolink Expert Patients-for-Patients Research network is an Italian-American non-profit dual organization promoted by scientists active in the field of Personalized Genomic Medicine (PGM) applied to Oncology and rare disease. The ISOPROG-Somatolink EPFP Network promotes partnership and cooperation with individual scientists, academic organizations and private industries in a worldwide landscape.